Skip to main content Back to Top
Advertisement

12/18/2017

Penicillin G Benzathine

Reason for the Shortage

    • Pfizer states the shortage was due to a delay in the manufacturing process.

Available Products

    • Bicillin L-A intramuscular suspension for injection, Pfizer, 1,200,000 units, 2 mL syringe, 10 count, NDC 60793-0701-10
    • Bicillin L-A intramuscular suspension for injection, Pfizer, 2,400,000 units, 4 mL syringe, 10 count, NDC 60793-0702-10
    • Bicillin L-A intramuscular suspension for injection, Pfizer, 600,000 units, 1 mL syringe, 10 count, NDC 60793-0700-10

Estimated Resupply Dates

    • Pfizer has Bicillin L-A 600,000 unit/ 1 mL syringes, 1,200,000 unit/ 2 mL syringes, and 2,400,000 unit/ 4 mL syringes available.

Implications for Patient Care

    • Bicillin L-A is the first line treatment of patients with syphilis. CDC is recommending conserving Bicillin L-A for patients with syphilis especially pregnant patients where the treatment choices are more limited. This recommendation can be found at http://www.cdc.gov/std/treatment/drugnotices/bicillinshortage.htm. More information regarding treatment of syphilis including alternatives to Bicillin L-A can be found at: http://www.cdc.gov/std/tg2015/syphilis.htm.

Updated

Updated December 18, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 30, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins